Sikkerhet og effekt av Silk Vista og Silk Vista Baby Flow Diverter for intrakraniell aneurismebehandling (FIRST)
Sikkerhet og effekt av Silk Vista og Silk Vista Baby Flow Diverter for intrakraniell aneurismebehandling, en observasjons, prospektiv, enarms, internasjonal multisenterstudie.
The FIRST study is an observational, prospective, multi-center, international, single-arm, study. The aim of the study is to collect safety and efficacy information on the use of the silk vista and silk vista baby flow diverter in order to assess clinical safety and performance of the device for treating intracranial aneurysms.
All patients with intracranial aneurysm ruptured or unruptured, whatever the localization of the aneurysm, and treated with silk vista or silk vista baby, will be consecutively enrolled in the study.
The patient's inclusion and follow up in the study will occur as part of their usual standard of care.
Studieoversikt
Status
Status
Forhold
Forhold
Intervensjon / Behandling
Intervensjon / Behandling
Studietype
Studietype
Registrering (Antatt)
Registrering
Kontakter og plasseringer
Studiesteder
-
-
-
Liège, Belgia, 4000
- CHC Saint Joseph Liège
-
-
-
-
-
Bordeaux, Frankrike, 33000
- CHU de Bordeaux - Hôpital Pellegrin
-
Brest, Frankrike, 29200
- Hopital Cavale Blanche
-
Bron, Frankrike, 69677
- Hospices Civils de Lyon - Hôpital Neurologique
-
Caen, Frankrike, 14033
- CHU Caen, Radiologie interventionelle
-
Clermont-Ferrand, Frankrike, 63003
- Centre Hospitalier Universitaire Clermont Ferrand
-
Grenoble, Frankrike, 38043
- Centre Hospitalier Universitaire de Grenoble Alpes
-
Le Kremlin-Bicêtre, Frankrike, 94270
- Hôpital Kremlin Bicêtre
-
Limoges, Frankrike, 87000
- Chu Dupuytren Limoges
-
Marseille, Frankrike, 13009
- Hôpital Privé Clairval
-
Paris, Frankrike, 75651
- Pitié-Salpêtrière Hospital
-
Paris, Frankrike, 75019
- Fondation Rothschild
-
Rouen, Frankrike, 76000
- CHU Chalre Nicolle
-
Tours, Frankrike, 37044
- Centre Hospitalier Régional Universitaire de Tours
-
-
-
-
-
Jerusalem, Israel, 9112001
- Hadassah Medical Center
-
Nahariya, Israel, 22100
- Galilee Medical Center
-
-
-
-
-
Milan, Italia, 20162
- Niguarda Hospital
-
Monza, Italia, 20900
- San Gerardo Hospital
-
Treviso, Italia, 31100
- Cà Foncello Hospital
-
Udine, Italia, 33100
- Santa maria della misericordia hospital
-
-
-
-
-
Zagreb, Kroatia, 10000
- University Hospital Centre Zagreb
-
-
-
-
-
Nijmegen, Nederland, 6525 G
- Radboud University medical Center
-
-
-
-
-
Barakaldo, Spania, 48903
- Hospital Universitario de cruces
-
Madrid, Spania, 28222
- Hopsital universidad puerta de hierro
-
Madrid, Spania, 28034
- Ramon y Cajal hospital
-
Oviedo, Spania, 33011
- Unversitario Central de Asturias
-
Valladolid, Spania, 47003
- Hospital Clinico Universitario de Valladolid
-
-
-
-
-
München, Tyskland, 81377
- Munich LMU University
-
-
-
-
-
Salzburg, Østerrike, A-5020
- Universitätsklinik für Neurologie
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Patients with an intracranial aneurysm treated with silk vista and silk vista baby.
Beskrivelse
Inclusion Criteria:
- Patient with intracranial aneurysms intended to be treated with the silk vista and silk vista baby (decision of use silk vista and silk vista baby is done independently and prior to the participation of the patient in the study)
- Patients with recanalized aneurysms previously treated with coils exclusively are also eligible.
- In case of multiple aneurysms, only treatment with silk vista and silk vista baby are allowed (between the initial index procedure to the 12 months follow up visit)
- Patient ≥ 18 years, who signed an informed consent.
Exclusion Criteria:
- Patient presenting with contra-indications to the use of silk vista and silk vista babyaccording to the IFU (Instruction for Use).
- Recanalized aneurysms initially treated with stent (including stent assisted coiling)
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Observasjonsmodeller: COHORT
- Tidsperspektiver: PROSPECTIVE
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Morbi-mortality of silk vista and silk vista baby in the treatment of intracranial aneurysms.
Tidsramme: At 12-months (-3 / + 6 months) post procedure
|
Characterized by the rate of the permanent neurologic deficits and procedure related mortality. |
At 12-months (-3 / + 6 months) post procedure
|
|
Morbi-mortality of silk vista and silk vista baby in the treatment of intracranial aneurysms.
Tidsramme: At 12-months (-3 / + 6 months) post procedure
|
Characterized by the clinical outcome assessed by mRS of the permanent neurologic deficits and procedure related mortality. |
At 12-months (-3 / + 6 months) post procedure
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Safety of silk vista and silk vista baby
Tidsramme: At T0
|
Assessed by the rate of adverse events |
At T0
|
|
Safety of silk vista and silk vista baby
Tidsramme: At hospital discharge
|
Assessed by the rate of adverse events |
At hospital discharge
|
|
Safety of silk vista and silk vista baby
Tidsramme: Up to 30 days (-10 / + 21 days) post- procedure.
|
Assessed by the rate of adverse events |
Up to 30 days (-10 / + 21 days) post- procedure.
|
|
Safety of silk vista and silk vista baby
Tidsramme: At 6 months (-2/+3 months) post- procedure.
|
Assessed by the rate of adverse events |
At 6 months (-2/+3 months) post- procedure.
|
|
Safety of silk vista and silk vista baby
Tidsramme: At 12 months (-3/+6 months) post- procedure.
|
Assessed by the rate of adverse events |
At 12 months (-3/+6 months) post- procedure.
|
|
Safety of silk vista and silk vista baby
Tidsramme: At 3 years post procedure
|
Assessed by the rate of adverse events |
At 3 years post procedure
|
|
Safety of silk vista and silk vista baby
Tidsramme: At 5 years post procedure
|
Assessed by the rate of adverse events |
At 5 years post procedure
|
|
Efficacy of silk vista and silk vista baby
Tidsramme: At T0
|
Assessed by aneurysm occlusion rate |
At T0
|
|
Efficacy of silk vista and silk vista baby
Tidsramme: At hospital discharge
|
Assessed by aneurysm occlusion rate |
At hospital discharge
|
|
Efficacy of silk vista and silk vista baby
Tidsramme: Up to 30 days (-10 / + 21 days) post- procedure.
|
Assessed by aneurysm occlusion rate |
Up to 30 days (-10 / + 21 days) post- procedure.
|
|
Efficacy of silk vista and silk vista baby
Tidsramme: Up to 6 months (-2/+3 months) post- procedure
|
Assessed by aneurysm occlusion rate |
Up to 6 months (-2/+3 months) post- procedure
|
|
Efficacy of silk vista and silk vista baby
Tidsramme: Up to 12 months (-3 / + 6 months) post procedure
|
Assessed by aneurysm occlusion rate |
Up to 12 months (-3 / + 6 months) post procedure
|
|
Efficacy of silk vista and silk vista baby
Tidsramme: Up to 3 years post procedure
|
Assessed by aneurysm occlusion rate |
Up to 3 years post procedure
|
|
Efficacy of silk vista and silk vista baby
Tidsramme: Up to 5 years post procedure
|
Assessed by aneurysm occlusion rate |
Up to 5 years post procedure
|
|
Technical procedure
Tidsramme: At T0
|
The practices related to the use of silk vista baby will be describe |
At T0
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Etterforskere
Etterforskere
- Hovedetterforsker: Mario Martinez Galdamez, Dr, Hospital Clinico Universitario de Valladolid (HCUV), Spain
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Studiestart
Primær fullføring (Faktiske)
Primær fullføring
Studiet fullført (Antatt)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
Andre studie-ID-numre
- CIP 201802 SILK VISTA
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .